What Cilostazol Treats: Main Uses and Benefits

Targeting Exercise-Induced Leg Pain (Intermittent Claudication)

This medication is primarily used to address the symptomatic discomfort of Intermittent Claudication, a condition marked by pain, cramping, or aching in the leg muscles that is associated with physical activity. This symptom is commonly managed in contexts involving chronic Peripheral Artery Disease (PAD). The treatment is utilized in clinical settings where symptoms are stable and are deemed lifestyle-limiting in adult patients. A key therapeutic benefit is to provide support that helps ease this exertion-related discomfort.

Restoring Functional Walking Capacity

The treatment is commonly used for managing symptoms that interfere with physical function; it may assist with supporting functional stability. The medication is relevant for easing symptoms that typically cluster around vascular claudication and reduced mobility, and is used when symptomatic assistance is needed. It is often applied in conditions involving recurrent or episodic manifestations. The medication may assist with managing symptoms that interfere with daily functioning, which may support improved endurance during walking. This general support for mobility and walking endurance may offer a practical advantage, assisting patients with maintaining a sense of stability when symptoms are more noticeable and supporting the management of daily activities.

Quick Fact: Symptomatic Focus
Primary Indication	Intermittent Claudication associated with Peripheral Artery Disease (PAD)
Symptom Relieved	Exercise-induced leg pain and cramping
Key Patient Benefit	Support for walking distance and endurance

Regulatory References

1. NIH MedlinePlus overview

Eligibility for Cilostazol

Cilostazol is approved only for adults with symptomatic Intermittent Claudication. Its use is defined primarily by numerous absolute contraindications mandated by regulatory authorities.

Classification	Population/Condition
Contraindicated	Heart failure of any severity (FDA Boxed Warning), Pregnancy, Severe Renal Impairment (Creatinine Clearance le 25 mL/min), and Moderate or Severe Hepatic Impairment.
Contraindicated	Recent Myocardial Infarction or Coronary Intervention (within the last 6 months), Unstable Angina Pectoris, or a history of severe tachyarrhythmia.
Contraindicated	Known predisposition to bleeding (e.g., active peptic ulceration, recent hemorrhagic stroke) or receiving two or more additional antiplatelet/anticoagulant agents.
Not Recommended	Lactation (Breastfeeding).
Use Not Established	The Paediatric population (children and adolescents).

Use in older adults has no special dosage requirements, but caution is required. Patients with stable coronary disease must be closely monitored during treatment.

Contraindicated Combinations

Official regulatory information states that Cilostazol is contraindicated for co-administration with two or more additional antiplatelet or anticoagulant agents (such as aspirin, clopidogrel, or warfarin). This restriction is based on the documented high risk of severe hemorrhagic events due to an additive pharmacodynamic effect.

---

Pharmacokinetic and Exposure Interactions

Cilostazol is metabolized by the cytochrome P450 enzymes CYP3A4 and CYP2C19. Co-administration with inhibitors of these enzymes is documented to increase the systemic exposure of Cilostazol or its active metabolite. For instance, strong CYP3A4 inhibitors (e.g., ketoconazole) significantly increase Cilostazol plasma concentrations (AUC).

---

Food and Timing Requirements

Administration of Cilostazol with a high-fat meal officially increases its bioavailability. To manage this interaction, regulatory labeling includes a mandatory timing rule: the medication must be taken on an empty stomach, specifically at least 30 minutes before or 2 hours after breakfast and dinner. Additionally, substances that inhibit CYP3A4, such as grapefruit juice, must be avoided as they are documented to increase the drug's maximal concentration (Cmax).

---

Population-Specific Notes

Official prescribing information notes that recommendations for dosing cannot be provided for patients with moderate or severe hepatic impairment due to a lack of clinical data.

️ How Цилостазол Works

Цилостазол (Cilostazol) operates through a highly targeted mechanism by acting as a selective inhibitor of the enzyme Phosphodiesterase type 3 (PDE3).

The core mechanism involves blocking the activity of the PDE3 enzyme found in vascular smooth muscle cells (VSMCs) and platelets. This inhibition prevents the degradation of the crucial cellular messenger, cyclic Adenosine Monophosphate (cAMP), causing its intracellular levels to rise significantly. This action initiates the entire pharmacodynamic cascade, which is also amplified by the drug's two active metabolites and its ability to inhibit adenosine uptake.

The elevated cAMP levels simultaneously modulate two key physiological processes. In VSMCs, the signaling boost relaxes the arterial smooth muscle, leading to vasodilation (vessel widening). Concurrently, in platelets, the increased cAMP suppresses the cellular steps required for them to activate and clump together, manifesting as suppressed platelet aggregation. This dual action of relaxing arteries and reducing clot-forming potential provides the physiological effect of increased blood flow and improved tissue perfusion. This integrated mechanistic approach acts upon two independent factors governing local blood flow: arterial smooth muscle tone and platelet activation state.

Official Administration Guidelines for Cilostazol

Cilostazol is administered exclusively by the oral route as a tablet, with the standard regimen for adults established as 100 mg twice daily.

A fundamental instruction for proper use involves the timing relative to food: the medication must be taken on an empty stomach. This specifically means taking the dose at least 30 minutes before or 2 hours after both the morning and evening meals to ensure correct absorption.

Dosage Adjustments and Course Duration

The standard dosing may require adjustment under specific administration conditions. When Cilostazol is co-administered with moderate or strong inhibitors of the CYP3A4 or CYP2C19 enzyme systems, the recommended dose should be reduced to 50 mg twice daily. This is a procedural step to maintain the appropriate level of the active substance.

In terms of duration, the protocol dictates a formal evaluation period. Treatment should be assessed after 3 months (12 weeks) of use. If the desired effects on functional capacity are not observed by this time, established instructions advise that the medication should be discontinued.

For cases of a missed dose, the procedural guidance is to simply skip the dose and take the next scheduled dose at the usual time; double doses should not be taken. No specific dosage adjustments are required for older adults or patients with mild hepatic or renal impairment (creatinine clearance greater than 25 ml/min).

Recent Clinical Evidence Summary

Clinical research on cilostazol has consistently focused on its use for intermittent claudication (IC), the leg pain caused by restricted blood flow due to peripheral arterial disease (PAD). Findings from multiple large-scale, placebo-controlled trials and meta-analyses establish the primary evidence profile for this compound.

---

Efficacy in Walking Distance

Randomized, double-blind trials, some lasting up to 24 weeks, consistently investigated whether use of cilostazol was associated with improvements in walking capacity. Relative to placebo, participants receiving cilostazol reported measurable differences in pain-free walking distance (PFWD) and maximal walking distance (MWD) on treadmill tests.

Research suggests that some improvement in walking capacity may be observed as early as four weeks into treatment and is maintained throughout the study duration. Subgroup analyses in these studies generally indicated similar responses across men and women, as well as in older and younger patient populations.

Safety and Additional Observations

Safety data collected across clinical trials indicate that the compound is generally tolerated by most subjects, though common adverse events reported were headache, diarrhea, and palpitations. These effects sometimes led to discontinuation in a small percentage of patients.

Furthermore, studies have reported secondary changes in lipid profiles, specifically observing an increase in high-density lipoprotein (HDL) cholesterol and a reduction in triglyceride levels in participants taking the compound, compared to placebo groups.

Common questions about Цилостазол (FAQ)

---

Q: Are there specific signs of a serious reaction to Цилостазол that require immediate medical attention?

Official safety information alerts patients to the risk of serious reactions, including severe bleeding and blood disorders. Patients are advised to watch for symptoms such as unusual weakness, fever, frequent infection, or easy bruising or bleeding.

Signs of a severe allergic reaction, such as breathing difficulties, swelling of the face or throat, or trouble swallowing, are noted as requiring immediate attention.

---

Q: How does the risk of bleeding from Цилостазол compare to other similar medications?

Regulatory analyses confirm that while this medication carries a risk of hemorrhage, the risk is managed primarily through contraindications, such as avoiding co-administration with two or more other antiplatelet or anticoagulant agents. Some clinical trial data has explored the comparative safety profile against other antiplatelet agents. Official labeling notes the importance of managing the additive risk when co-administered with other antiplatelet drugs.

---

Q: Does alcohol consumption interact with Цилостазол?

Official patient materials state that combining alcohol with this medication may potentially increase the risk of certain side effects. Specifically, there may be an increased potential for dizziness or fainting spells when this drug is used concurrently with alcohol.

---

Q: Are there any common over-the-counter stomach medicines that can interact with Цилостазол?

Yes, official drug interaction warnings specifically mention that certain stomach medicines, such as those containing omeprazole, may interact with Цилостазол. This interaction occurs because these medications inhibit the CYP2C19 enzyme, and this is listed as a condition that may require a change in the prescribed regimen.

---

Q: What kind of monitoring, like blood tests, might be needed while taking Цилостазол?

Because the medication has been associated with rare reports of serious hematological adverse reactions (blood disorders), official documents advise patients to keep all appointments for regular blood checks. This monitoring is intended to detect potential blood problems promptly.

---

Q: What are the known effects of Цилостазол on blood pressure?

Official product information indicates that, due to the drug's effect of widening blood vessels (vasodilation), it may cause a temporary increase in heart rate (tachycardia) and can potentially lead to low blood pressure (hypotension). Caution is generally advised when this drug is used alongside other medications that also lower blood pressure.

---

Q: Is there evidence that Цилостазол helps improve quality of life?

Clinical trials consistently established that the medication increases both pain-free and maximal walking distances for patients with intermittent claudication. Regulatory summaries conclude that this established functional improvement is considered clinically relevant and suggests an overall enhancement in quality of life for certain patients.

---

Q: What should be done if I experience increased bruising while taking Цилостазол?

Since the drug acts as an antiplatelet agent, unusual or increased bruising is noted in official safety materials as a potential sign of bleeding. Official safety materials advise contacting a healthcare provider immediately for evaluation if easy bruising or bleeding is experienced.

---

Q: Why is there a recommendation to stop Цилостазол several days before elective surgery?

Regulatory guidance indicates temporary discontinuation is advised for antiplatelet agents, typically about five days before planned elective surgery. This temporary cessation is recommended to help manage and minimize the risk of bleeding during the surgical procedure.

---

Q: Can I stop taking Цилостазол suddenly, or does it need to be done gradually?

Official protocols for planned temporary cessation (such as before surgery) indicate that due to its relatively short half-life, the medication's antiplatelet effects diminish naturally, and a slow, gradual tapering is not usually required.

---

Q: Is the brand name Pletal the same drug as generic Цилостазол?

Yes, regulatory and official drug information sources confirm that Pletal is the registered brand name under which the drug is commonly sold. Цилостазол is the International Nonproprietary Name (INN) for the core active substance and is available in generic form.

---

Q: Does Цилостазол have any known effects on kidney function?

Official labeling primarily addresses patient eligibility, noting that caution is required for patients with severe pre-existing kidney impairment. The medication is generally acceptable for use in patients with mild kidney problems, with no dosage adjustment required for this group.

Storage and Disposal of Cilostazol Tablets

Cilostazol tablets must be stored at Controlled Room Temperature, defined as 20 to 25 C (68 to 77 F), with permitted short excursions. The medication must be kept in its tightly closed, original container and protected from excess heat and moisture. Do not store the tablets in environments like the bathroom due to high humidity.

Child Safety and Disposal

It is essential to keep Cilostazol tablets strictly out of the reach of children, securing them in a location that is up and away and out of sight. Unused or expired tablets should be discarded according to official guidelines. Consult a pharmacist, doctor, or local waste disposal company about community drug take-back programs for proper pharmaceutical disposal.